Trovafloxacin was found to be a typical quinolone producing a biphasic dose response against Escherichia coli, Staphylococcus aureus or Streptococcus pneumoniae. A reduced rate of kill was seen against Enterococcus faecalis, which is also typical of the quinolones. However, the bactericidal activity of trovafloxacin against S. aureus and S. pneumoniae was greater than most other quinolones previously tested. The enhanced bactericidal activity of trovafloxacin against S. aureus may be explained by the possession of a very strong bactericidal mechanism B. Trovafloxacin may prove to be a quinolone of choice against S. aureus infections.
Introduction
Many quinolones have been included in a series of studies into bactericidal activity and bactericidal mechanisms of action (as described in Morrissey & Smith, 1995) . These studies have the advantage that the same test method and strains have been used throughout. It has been shown that the quinolones possess four bactericidal mechanisms of action, known as mechanisms, A, B, Bi and C. Mechanism A, the basic quinolone mechanism, is the sole mechanism of action shown by older quinolones such as nalidixic acid. This mechanism requires bacteria to be undergoing multiplication and protein or RNA synthesis (Lewin, Morrissey & Smith, 1991a) . Mechanism B is an additional mechanism shown by several modern quinolones (Morrissey & Smith, 1995) . This bactericidal mechanism is active against non-dividing bacteria and does not require active protein or RNA synthesis (Lewin el al., 1991a) . A related bactericidal mechanism, B,, has also been identified, but only with clinafloxacin. This mechanism does not require protein or RNA synthesis but does require dividing bacteria (Lewin & Amyes, 1990a) . Mechanism C, on the other hand, does not require bacterial multiplication, but does require active protein or RNA synthesis (Lewin et al., 1991a) . This mechanism has been found with norfloxacin (Ratcliffe & Smith, 1985) and enoxacin (Lewin, Amyes & Smith, 1989) only.
I. Monissey
staphylococcal infections may be due to a lack of additional bactericidal mechanisms such as mechanism B, B, or C It is important to assess the bactericidal activity of quinolones in addition to bacteriostatic activity (i.e. MIC studies) as these two activities are quite distinct. For example, quinolones show relatively poor MICs against Pseudomonas aeruginosa compared with other Gram-negative bacteria. However, quinolones are considerably more bactericidal against P. aeruginosa than against any other bacterial species (Morrissey & Smith, 1994) . It therefore follows that quinolone MICs and optimum bactericidal concentrations do not correlate. Furthermore, factors such as pH and magnesium ions, have dissimilar effects on the bacteriostatic and bactericidal activities of quinolones (Smith & Lewin, 1988) .
This study was carried out to assess the bactericidal activity of the new quinolone trovafloxacin. Previous investigations suggest that trovafloxacin has enhanced activity compared to other quinolones especially against Enlerococcus faecalis and Streptococcus pneumoniae (Gootz el al., 1994; Paris et al., 1995) .
Materials and methods

Drug solutions
Trovafloxacin powder (CP-99,219) (Pfizer, USA) of known potency was dissolved immediately before use in 0.1 M NaOH to 2.5 mg/mL and then further diluted in sterile distilled water as necessary. Chloramphenicol (Sigma, Poole, UK) was firstly dissolved in methanol and then diluted in sterile distilled water.
Test strains
Escherichia coli K.L16, Staphylococcus aureus E3T, S. pneumoniae C3LN4 and E. faecalis ATCC19433 were used in this study. These strains were chosen due to their use in previous studies into the bactericidal activity of numerous quinolones. 
Bactericidal tests and assessment for bactericidal mechanisms of action
The bactericidal activity of trovafloxacin was investigated using the method of Morrissey & Smith (1995) . Briefly, a range of drug concentrations between 0.015 and 90 mg/L was prepared in Oxoid nutrient broth No. 2 (Unipath, Basingstoke, UK). Bacteria were inoculated to an initial inoculum size of about 10 7 cfu/mL and incubated for 3 h at 37°C. For studies using S. pneumoniae, laked horse blood (Unipath) was added to 7% (v/v). Due to the slow bactericidal activity of quinolones against E. faecalis, incubation times were extended to 6 and 24 h when this organism was tested. The presence of additional bactericidal mechanisms B, B, or C were assessed by the addition of 20 mg/L chloramphenicol (2.5 mg/L for S. pneumoniae) to prevent protein synthesis or by replacing nutrient broth with phosphate-buffered saline (PBS) to prevent bacterial multiplication. To prevent autolysis of S. pneumoniae, horse serum (Sera Lab) at 7% (v/v) was added when this organism was studied in PBS. After incubation viable counts were made on solid agar. Experiments were carried out in duplicate and average results plotted as percent survival against drug concentration tested.
Results
Bactericidal tests
Trovafloxacin produced biphasic dose response curves against E. coli, S. aureus and S. pneumoniae (results not shown), characteristic of the quinolone antibacterials (Lewin et al., 1991a) , producing specific optimum bactericidal concentrations (OBCs). The OBCs for trovafloxacin and other quinolones against E. coli and S. aureus are shown in the Table I . Trovafloxacin compares favourable with other quinolones with respect to OBC, especially against S. aureus.
The activity of trovafloxacin and other quinolones against S. pneumoniae are shown in Table II , where it can be seen that trovafloxacin shared the second lowest OBC against S. pneumoniae. Trovafloxacin produced lower percentage survival than established quinolones, but was less potent than the experimental quinolones DU-6859a or DV-7751a.
When E. faecalis was treated with trovafloxacin, weak bactericidal activity occurred in nutrient broth after the first 3 h, however, when incubation was extended to 6 and 24 h, greater bactericidal activity was apparent (Table III) . This slow bactericidal activity against E. faecalis is a characteristic shared by the majority of quinolones (Lewin, Morrissey & Smith, 1991*; Lewin, 1992 with trovafloxacin at the respective OBCs in nutrient broth alone, nutrient broth plus chloramphenicol or PBS are shown in Table III . Survival was lower in the presence of chloramphenicol or in PBS than when in nutrient broth alone. However, significant kill occurred with trovafloxacin against E. coli or S. aureus in the presence of chloramphenicol or in PBS. These results show that trovafloxacin possessed the additional bactericidal mechanism B against these two bacterial species. Bactericidal mechanism B was particularly strong against S. aureus, which may explain the enhanced potency of trovafloxacin against this bacterium. Furthermore, trovafloxacin showed greater bactericidal activity against S. aureus than against E. coli, which is unusual and suggests further evidence of trovafloxacin's excellent activity against S. aureus.
Against S. pneumoniae, however, little or no kill occurred in the presence of chloramphenicol or in PBS. These results show that trovafloxacin possesses only bactericidal mechanism A against this organism. This is a common phenomenon seen with quinolones (Morrissey & Smith, 1993) . Similarly, trovafloxacin showed only bactericidal mechanism A against E. faecalis at 3 and 6h (Table III) . This is also characteristic of the majority of quinolones (Lewin et al., 19916; Lewin, 1992) . However, as trovafloxacin produced some bactericidal activity in nutrient broth plus chloramphenicol after 24 h, weak bactericidal mechanism B, may be present.
Discussion
The bactericidal activity of trovafloxacin against E. coli, as measured by OBCs, would appear to be equivalent to that seen with other quinolones. However, trovafloxacin showed enhanced bactericidal activity against S. aureus. The excellent bactericidal activity of trovafloxacin against S. aureus may be explained by the possession of a strong additional bactericidal mechanism B against this organism. The possession of mechanism B by a quinolone is highly advantageous as it allows for bactericidal activity against non-dividing bacteria. Gootz et al. (1994) also found that trovafloxacin showed excellent bactericidal activity against S. aureus. Trovafloxacin was more bactericidal than ciprofloxacin or sparfloxacin. It is interesting that ciprofloxacin does not possess mechanism B against 5. aureus (Lewin & Smith, 1988) and sparfloxacin has only a weak mechanism B (Lewin, Morrissey & Smith, 1992) . The possession of a strong mechanism B by trovafloxacin against S. aureus may be of importance because with this mechanism, dormant bacteria at sites of infection should be susceptible to trovafloxacin while other quinolones such as ciprofloxacin or sparfloxacin may be ineffectual.
Trovafloxacin also showed enhanced bactericidal activity against S. pneumoniae in this study. However, this cannot be explained by the presence of any additional bactericidal mechanism because only mechanism A was found against this organism. Nevertheless, the bactericidal activity of trovafloxacin against S. pneumoniae was considerably greater than that found with established quinolones which also only possess mechanism A against this organism (Morrissey & Smith, 1993) . This may explain the improved activity of trovafloxacin against pneumococcal infections in animal models (Paris et al., 1995) .
To conclude, trovafloxacin would appear to have greater bactericidal activity than clinically available quinolones, though in most cases, this drug would not appear to be as potent as the developmental quinolone DU-6859a (Morrissey & Smith, 1995) . However, against S. aureus, trovafloxacin was highly active and was as bactericidal as any quinolone so far tested. Trovafloxacin therefore shows potential in the treatment of staphylococcal infections. The bactericidal data shown in this study, suggest that further investigation into the activity of trovafloxacin against other strains of S. aureus including methicillin-resistant S. aureus is necessary.
